Lv1
48 积分 2024-04-05 加入
Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis
8天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
8天前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
23天前
已完结
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
3个月前
已完结
Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis
3个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
3个月前
已完结
Mechanisms and Treatment of CKD
3个月前
已完结
Predicting the Risk for Dialysis or Death in IgA Nephropathy
3个月前
已完结
Predicting progression in IgA nephropathy
3个月前
已完结
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus
4个月前
已完结
皖公网安备34019202002308
